{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:52:33Z","timestamp":1792705953622,"version":"4.5.0"},"reference-count":37,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>To date, no psychopharmacologic treatment has been found to be uniformly effective in veterans with posttraumatic stress disorder (PTSD); novel targets and approaches are needed to treat this disabling disorder.<\/jats:p><\/jats:sec>Objective<\/jats:title>To examine whether treatment with the glucocorticoid receptor antagonist mifepristone yields a signal for clinical efficacy in male veterans with PTSD.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This phase 2a, double-blind, parallel-group randomized clinical trial was conducted from November 19, 2012 (accrual started), through November 16, 2016 (final follow-up), within the US Department of Veterans Affairs. Participants were male veterans with chronic PTSD and a screening Clinician-Administered PTSD Scale score of 50 or higher. A total of 181 veterans consented to participation. Statistical analysis was conducted between August 2014 and May 2017.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Participants were randomized in a 1:1 ratio to mifepristone (600 mg) or matched placebo taken orally for 7 days.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The clinical outcome was whether a veteran achieved a clinical response status (a reduction of \u226530% of total Clinician-Administered PTSD Scale score from baseline) at 4- and 12-week follow-up. On the basis of a binary statistical selection rule, a difference in the proportion of treatment vs control group responders of 15% would be a clinically relevant difference. Self-report measures of PTSD and associated symptoms were also obtained. Neuroendocrine outcomes and plasma levels of mifepristone were measured. Safety was assessed throughout the study. The primary analysis was based on a multiple imputation technique to address missing outcome data; thus, some participant numbers may not appear as whole numbers.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 81 veterans were enrolled and randomized. Excluding 1 participant randomized in error, 80 were included in the modified intention-to-treat analysis (41 randomized to mifepristone and 39 to placebo). The mean (SD) age was 43.1 (13.7) years. A total of 15.6 (38.1%) in the mifepristone group and 12.1 (31.1%) in the placebo group were clinical responders at 4 weeks in the analysis using the multiple imputation technique. The group difference in the proportion of clinical responders (7.0%) was less than the predefined margin of 15% indicating signal for clinical efficacy. In an exploratory analysis, the difference in response to mifepristone vs placebo in the subgroup with no lifetime history of traumatic brain injury (TBI) (7.0 [50.0%] vs 3.0 [27.3%]; difference, 22.7%) exceeded the efficacy margin at 4 weeks and was sustained at 12 weeks. In contrast, in veterans with PTSD and lifetime TBI, the response rate to mifepristone was lower than placebo at 12 weeks (7.4 [27.4%] vs 13.5 [48.3%]; difference, \u221220.9%).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This study did not detect a signal for efficacy for mifepristone at 600 mg\/d for 1 week in male veterans with chronic PTSD. Thus, this study does not support a phase 3 trial in this population. Future studies of mifepristone for the treatment of PTSD may be of interest in those without a history of TBI or in samples with a low base rate of lifetime head trauma.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT01946685<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.10223","type":"journal-article","created":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T19:50:41Z","timestamp":1683661841000},"page":"e2310223","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and Safety of Mifepristone in the Treatment of Male US Veterans With Posttraumatic Stress Disorder"],"prefix":"10.1001","volume":"6","author":[{"given":"Julia A.","family":"Golier","sequence":"first","affiliation":[{"name":"Veterans Affairs (VA) Medical Center, Bronx, New York"},{"name":"Department of Psychiatry, Mount Sinai School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Li","sequence":"additional","affiliation":[{"name":"VA Cooperative Studies Program, Hines, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Bizien","sequence":"additional","affiliation":[{"name":"VA Cooperative Studies Program Clinical Research Coordinating Center, Albuquerque, New Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin A.","family":"Hurley","sequence":"additional","affiliation":[{"name":"VA Medical Center, Salisbury, North Carolina"},{"name":"Department of Psychiatry and Radiology, Wake Forest School of Medicine, Winston-Salem, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan W.","family":"Bechard","sequence":"additional","affiliation":[{"name":"Veterans Affairs (VA) Medical Center, Bronx, New York"},{"name":"Department of Psychiatry, Mount Sinai School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Kimbrell","sequence":"additional","affiliation":[{"name":"Central Arkansas VA Healthcare, University of Arkansas, Fayetteville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine D.","family":"Flory","sequence":"additional","affiliation":[{"name":"Veterans Affairs (VA) Medical Center, Bronx, New York"},{"name":"Department of Psychiatry, Mount Sinai School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dewleen G.","family":"Baker","sequence":"additional","affiliation":[{"name":"VA San Diego Healthcare System, University of California, San Diego, San Diego"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Yehuda","sequence":"additional","affiliation":[{"name":"Veterans Affairs (VA) Medical Center, Bronx, New York"},{"name":"Department of Psychiatry, Mount Sinai School of Medicine, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenic J.","family":"Reda","sequence":"additional","affiliation":[{"name":"VA Cooperative Studies Program, Hines, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"issue":"3","key":"zoi230328r1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.20m13522","article-title":"Trends in medication prescribing in patients with PTSD from 2009 to 2018: a national Veterans Administration study.","volume":"82","author":"Holder","year":"2021","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"zoi230328r2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/10401230009147096","article-title":"Lack of efficacy for fluoxetine in PTSD: a placebo controlled trial in combat veterans.","volume":"12","author":"Hertzberg","year":"2000","journal-title":"Ann Clin Psychiatry"},{"issue":"2","key":"zoi230328r3","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/00004714-200204000-00013","article-title":"Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder.","volume":"22","author":"Zohar","year":"2002","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"zoi230328r4","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1507598","article-title":"Trial of prazosin for post-traumatic stress disorder in military veterans.","volume":"378","author":"Raskind","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"zoi230328r5","first-page":"55","article-title":"How do glucocorticoids influence stress responses? integrating permissive, suppressive, stimulatory, and preparative actions.","volume":"21","author":"Sapolsky","year":"2000","journal-title":"Endocr Rev"},{"issue":"5","key":"zoi230328r6","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.psyneuen.2012.08.007","article-title":"Mineralocorticoid and glucocorticoid receptor balance in control of HPA axis and behaviour.","volume":"38","author":"Harris","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"zoi230328r7","first-page":"29","article-title":"Risk and resilience in posttraumatic stress disorder.","volume":"65","author":"Yehuda","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"zoi230328r8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10571-018-0614-5","article-title":"Resetting the stress system with a mifepristone challenge.","volume":"39","author":"Dalm","year":"2019","journal-title":"Cell Mol Neurobiol"},{"issue":"1","key":"zoi230328r9","first-page":"33","article-title":"Mifepristone (RU-486) treatment for depression and psychosis: a review of the therapeutic implications.","volume":"2","author":"Gallagher","year":"2006","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"zoi230328r10","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1097\/00004714-200110000-00009","article-title":"Rapid reversal of psychotic depression using mifepristone.","volume":"21","author":"Belanoff","year":"2001","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"zoi230328r11","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/sj.npp.1300884","article-title":"Clinical and biological effects of mifepristone treatment for psychotic depression.","volume":"31","author":"Flores","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"zoi230328r12","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.biopsych.2006.05.034","article-title":"Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression.","volume":"60","author":"DeBattista","year":"2006","journal-title":"Biol Psychiatry"},{"issue":"5","key":"zoi230328r13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/JCP.0000000000000744","article-title":"Mifepristone plasma level and glucocorticoid receptor antagonism associated with response in patients with psychotic depression.","volume":"37","author":"Block","year":"2017","journal-title":"J Clin Psychopharmacol"},{"issue":"1","key":"zoi230328r14","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1176\/ajp.150.1.83","article-title":"Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder.","volume":"150","author":"Yehuda","year":"1993","journal-title":"Am J Psychiatry"},{"issue":"4","key":"zoi230328r15","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.biopsych.2014.02.006","article-title":"Lower methylation of glucocorticoid receptor gene promoter 1F in peripheral blood of veterans with posttraumatic stress disorder.","volume":"77","author":"Yehuda","year":"2015","journal-title":"Biol Psychiatry"},{"issue":"4","key":"zoi230328r16","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1176\/ajp.156.4.585","article-title":"Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder.","volume":"156","author":"Baker","year":"1999","journal-title":"Am J Psychiatry"},{"key":"zoi230328r17","article-title":"A pilot study of mifepristone in combat-related PTSD.","volume":"2012","author":"Golier","year":"2012","journal-title":"Depress Res Treat"},{"issue":"10","key":"zoi230328r18","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.biopsych.2007.04.027","article-title":"Twenty-four hour plasma cortisol and adrenocorticotropic hormone in Gulf War veterans: relationships to posttraumatic stress disorder and health symptoms.","volume":"62","author":"Golier","year":"2007","journal-title":"Biol Psychiatry"},{"key":"zoi230328r19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.psyneuen.2015.11.001","article-title":"A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness.","volume":"64","author":"Golier","year":"2016","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"zoi230328r20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/(ISSN)1573-6598","article-title":"The development of a clinician-administered PTSD scale.","volume":"8","author":"Blake","year":"1995","journal-title":"J Trauma Stress"},{"issue":"6","key":"zoi230328r21","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1097\/01.HTR.0000300227.67748.77","article-title":"Initial reliability and validity of the Ohio State University TBI Identification Method.","volume":"22","author":"Corrigan","year":"2007","journal-title":"J Head Trauma Rehabil"},{"issue":"12","key":"zoi230328r22","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults.","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"issue":"3 pt 1","key":"zoi230328r23","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2466\/pr0.96.3.771-774","article-title":"Validity of the Miller forensic assessment of symptoms test in psychiatric inpatients.","volume":"96","author":"Veazey","year":"2005","journal-title":"Psychol Rep"},{"key":"zoi230328r24","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","article-title":"An inventory for measuring depression.","volume":"4","author":"Beck","year":"1961","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"zoi230328r25","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research.","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res"},{"issue":"8","key":"zoi230328r26","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/0005-7967(96)00033-2","article-title":"Psychometric properties of the PTSD Checklist (PCL).","volume":"34","author":"Blanchard","year":"1996","journal-title":"Behav Res Ther"},{"issue":"12","key":"zoi230328r28","first-page":"1375","article-title":"Randomized phase II clinical trials.","volume":"69","author":"Simon","year":"1985","journal-title":"Cancer Treat Rep"},{"issue":"14","key":"zoi230328r31","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1001\/jama.283.14.1837","article-title":"Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial.","volume":"283","author":"Brady","year":"2000","journal-title":"JAMA"},{"issue":"1","key":"zoi230328r32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/00004714-200202000-00021","article-title":"Valproate therapy for chronic, combat-induced posttraumatic stress disorder.","volume":"22","author":"Petty","year":"2002","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"zoi230328r33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1176\/rcp2.v1.2","article-title":"A multisite randomized controlled trial of mindfulness-based stress reduction in the treatment of posttraumatic stress disorder.","volume":"1","author":"Davis","year":"2019","journal-title":"Psychiatr Res Clin Pract"},{"issue":"5","key":"zoi230328r36","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1056\/NEJMoa072972","article-title":"Mild traumatic brain injury in U.S. soldiers returning from Iraq.","volume":"358","author":"Hoge","year":"2008","journal-title":"N Engl J Med"},{"key":"zoi230328r37","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.psyneuen.2015.02.008","article-title":"The role of biomarkers and MEG-based imaging markers in the diagnosis of post-traumatic stress disorder and blast-induced mild traumatic brain injury.","volume":"63","author":"Huang","year":"2016","journal-title":"Psychoneuroendocrinology"},{"key":"zoi230328r27","volume-title":"Professional Manual","author":"Spielberger","year":"1988"},{"key":"zoi230328r29","year":"2001"},{"key":"zoi230328r30","doi-asserted-by":"crossref","DOI":"10.1137\/1.9781611971101","volume-title":"Selecting and Ordering Populations: A New Statistical Methodology","author":"Gibbons","year":"1999"},{"key":"zoi230328r34","doi-asserted-by":"crossref","DOI":"10.1002\/9780470510445","volume-title":"Missing Data in Clinical Studies","author":"Molenberghs","year":"2007"},{"key":"zoi230328r35","volume-title":"Applied Longitudinal Analysis","author":"Fitzmaurice","year":"2012"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2804657\/golier_2023_oi_230328_1683041699.20927.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T19:50:53Z","timestamp":1683661853000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2804657"}},"subtitle":["A Phase 2a Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.10223","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]}}}